Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome

Molecules. 2019 Nov 6;24(22):4019. doi: 10.3390/molecules24224019.

Abstract

Prostaglandins and inhibitors of their synthesis (cyclooxygenase (COX) inhibitors, non-steroidal anti-inflammatory drugs) were shown to play a significant role in the regulation of hematopoiesis. Partly due to their hematopoiesis-modulating effects, both prostaglandins and COX inhibitors were reported to act positively in radiation-exposed mammalian organisms at various pre- and post-irradiation therapeutical settings. Experimental efforts were targeted at finding pharmacological procedures leading to optimization of therapeutical outcomes by minimizing undesirable side effects of the treatments. Progress in these efforts was obtained after discovery of selective inhibitors of inducible selective cyclooxygenase-2 (COX-2) inhibitors. Recent studies have been able to suggest the possibility to find combined therapeutical approaches utilizing joint administration of prostaglandins and inhibitors of their synthesis at optimized timing and dosing of the drugs which could be incorporated into the therapy of patients with acute radiation syndrome.

Keywords: acute radiation syndrome; cyclooxygenase; gastrointestinal system; hematopoiesis; inhibitors of prostaglandin synthesis; prostaglandins.

Publication types

  • Review

MeSH terms

  • Acute Radiation Syndrome / blood
  • Acute Radiation Syndrome / drug therapy
  • Acute Radiation Syndrome / etiology
  • Acute Radiation Syndrome / metabolism*
  • Animals
  • Cyclooxygenase 1 / metabolism
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase 2 Inhibitors / pharmacology
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Disease Models, Animal
  • Hematopoiesis / drug effects*
  • Humans
  • Metabolic Networks and Pathways / drug effects
  • Prostaglandins / biosynthesis*
  • Prostaglandins / pharmacology*
  • Radiation-Protective Agents / pharmacology*
  • Radiation-Protective Agents / therapeutic use

Substances

  • Cyclooxygenase 2 Inhibitors
  • Prostaglandins
  • Radiation-Protective Agents
  • Cyclooxygenase 1
  • Cyclooxygenase 2